Paul Glue

Paul Glue is a clinician‑researcher whose work centres on clinical and early‑phase trials of rapid‑acting and non‑classic psychedelic compounds for psychiatric indications. His trial portfolio includes ascending‑dose and single‑dose safety studies of noribogaine in both healthy volunteers and opioid‑dependent patients, randomised controlled and pragmatic evaluations of subcutaneous and intranasal ketamine for treatment‑resistant depression (including economic evaluations), and experimental studies of low‑dose ibogaine on mood and cognitive performance. Glue's clinical research typically emphasises pharmacokinetics, pharmacodynamics, safety and tolerability, and uses randomised, double‑blind, placebo‑controlled or active‑controlled designs where feasible.

In addition to investigator‑led trials, Glue has contributed to reviews and evidence briefs synthesising the safety and efficacy literature for psychedelics in mental health and substance use disorders. His publications and trial work have informed discussion on dosing strategies, adverse‑event monitoring, and pragmatic considerations for implementing rapid‑acting psychopharmacological interventions in clinical settings. Overall, his contributions bridge early‑phase human pharmacology and applied clinical trial research in psychedelic and rapid‑acting therapies.